SCHEMBL6718890

SCHEMBL6718890

Cc1ccccc1NC(=O)C(N)C(F)(F)F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
POLB P06746 2/20 0.53
PDK1 Q15118 1/20 0.53
PDK2 Q15119 1/20 0.53
PDK3 Q15120 1/20 0.53
PDK4 Q16654 1/20 0.53
MAPT P10636 2/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
HPGD P15428 3/20 0.51
ALDH1A1 P00352 1/20 0.51
PGR P06401 1/20 0.49
SCN1A P35498 1/20 0.49
SCN2A Q99250 1/20 0.49
SCN3A Q9NY46 1/20 0.49
GAA P10253 2/20 0.48
LMNA P02545 1/20 0.48
DDX3X O00571 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8345708 0.85 RAB9A (0.55) RAB9ANPC1POLBPDK1PDK2
SCHEMBL10661382 0.81 RAB9A (0.53) RAB9ANPC1POLBPDK1PDK2
Formic Acid SCHEMBL6719239 0.80 POLB (0.49) RAB9ANPC1POLBPDK1PDK2
SCHEMBL8346804 0.80 NPC1 (0.60) RAB9ANPC1POLBMAPTHTT
SCHEMBL8344357 0.80 NPC1 (0.60) RAB9ANPC1POLBMAPTHTT
SCHEMBL6723897 0.77 MAPT (0.49) RAB9ANPC1POLBPDK1PDK2
SCHEMBL6715814 0.77 NPC1 (0.56) RAB9ANPC1POLBMAPTHTT
SCHEMBL6717651 0.77 NPC1 (0.56) RAB9ANPC1POLBMAPTHTT
SCHEMBL8347817 0.77 NPC1 (0.56) RAB9ANPC1POLBMAPTHTT
SCHEMBL5186841 0.75 MDM4 (0.67) RAB9ANPC1POLBMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 RAB9A 2094/4885NPC1 120/4885POLB 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.